Research Progress of Multi-target CAR-T Cell Therapy for Cancer
10.3971/j.issn.1000-8578.2022.21.1224
- VernacularTitle:多靶点CAR-T细胞治疗肿瘤的研究进展
- Author:
Yao JIANG
1
;
Weihong WEN
;
Fa YANG
;
Disen NIE
;
Wuhe ZHANG
;
Weijun QIN
Author Information
1. Department of Urology, Xijing Hospital of Air Force Military Medical University, Xi'an 710054, China
- Publication Type:Research Article
- Keywords:
Malignant tumor;
CAR-T cell;
Off-target effects
- From:
Cancer Research on Prevention and Treatment
2022;49(7):709-714
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors. CAR-T cell therapy has shown remarkable antitumor efficacy for the treatment of tumors, especially for hematological malignancies, but is less effective in solid tumors. Single-target CAR-T is prone to off-target effect during application, and there is a risk of relapse or more refractory treatment. The development of double-target or multi-target CAR-T is expected to extend the antigen coverage of target cells, effectively avoids antigen escape and prevents tumor recurrence, and prolongs the survival time of patients. This article reviews the advances of multi-target chimeric antigen receptor T cell, and discusses the prospect of its development.